Key points
- After a slow spring, ultra-rich investment companies made 60 direct investments in June, according to Fintrx.
- Family offices clashed towards biotechnology and health care companies such as Antheia, seeking to have an impact and come back at the same time.
- Antheia’s founder Christina Smolke told CNBC Patient Capital, the capital of the family of wealth families, which made them invest in scientific breakthroughs.
A version of this article appeared for the first time in Inside Wealth Newsletter of CNBC with Robert Frank, a weekly guide to the investor and consumer with high shuttle. Register to receive future editions, directly in your reception box. For ultra-rich investment companies, the conclusion of transactions is warmed up. In June, family offices made 60 direct investments in companies, ending three consecutive months of drop in the activity of the agreement, according to data provided exclusively at CNBC by FINTRX. The June count is an improvement compared to the 47 transactions recorded in May, although it marks a 40% drop over one year on the other, according to the private wealth platform. June saw some buzzing entertainment offers. The investment company for the founding family of Nintendo bought a minority participation in Indie Film Studio K2 Pictures for a non -disclosed amount. Yamauchi No. 10 Family Office also invests in the startup film production fund, a Hollywood financing strategy that is rare in Japan. Statersid, the Billionaire Blackstone David Blitzer joined a fundraising of $ 20 million for Ballers, a member club for sports, including Padel and Virtual Golf. A multitude of professional athletes, including tennis Hall of Famer, Andre Agassi, also participated in the round. But biotechnology and health care proved to be more popular themes, representing nine agreements by families of heavy strikers. The Narcan Antheia ingredient manufacturer has raised a C series of $ 56 million with investors, including ATHOS KG and S-Cubed Capital family offices. The directors of Athos KG, the billionaire twins Andreas and Thomas Strüngmann, made a fortune with a manufacturer of generic hexal medication and invested in the manufacturer of Vaccines led Biontech. Cube capital is managed by the billionaire and former partner of Sequoia, Mark Stevens. The former CEO of Google, Eric Schmidt, Hillspire is an investor in Antheia since his 73 million dollars B series in 2021. Christina Smolke, a scientist who became the entrepreneur, co-founded Antheia in 2015 after discovering how the yeast of yeasts to make opioids for medical use in less than two weeks. As a rule, the hydrocodone production process from opium popp can take two years between agriculture, harvesting and extraction, Smolke said in an interview with CNBC. Smolke, professor of Stanford with a doctorate. In chemical engineering, said in the wealth that family offices, which tend to invest with long investment horizons, are well suited to biotechnology investments. “These are complicated problems. There is not a kind of fast patch that we are going to set up,” she said. “Family offices tend to be able to be patient with their investments, and who align themselves very well with the cycles and deadlines necessary for biotechnology and to provide new products, new technologies and a new transformation, in the system, to health care.” At the end of 2024, Antheia launched her first product, Thebaine, a key ingredient in overdose Narcan reversal medications. The recent fundraising will allow Antheia to extend Europe production in the United States and put other products on the market. The company based in Menlo Park, California, develops 70 pharmaceutical ingredients necessary for the drugs used to treat cancer, bacterial infections, convulsions and other conditions. “The main aspect which is shared through all this is to be able to rebuild these supply chains in essential medicine so that the shortages of drugs become one thing in the past and access, on a global scale, becomes more equitable,” she said. For family -oriented family offices, biotechnology can serve as a familiar border, said Smolke. “This can speak very directly to investors,” she said. “I think everyone has really experienced challenges directly with drug shortages – even in the United States – to go to the supermarket and have cold drugs out of stock or not be able to obtain certain antibiotics.”